Clinical Trial Update: Gepaktiv vs UDCA and Ademetionine in MAFLD With Hepatomegaly [NA]

View source ↗

Summary

A clinical study comparing Gepaktiv to ursodeoxycholic acid (UDCA) and ademetionine in metabolic dysfunction-associated fatty liver disease (MAFLD) with hepatom…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Fatty Liver Disease
• Hepatomegaly
• Metabolic Dysfunction-associated Fatty Liver Disease
• Nonalcoholic Fatty Liver Disease

Drugs mentioned

• Ademetionine (S-adenosyl-L-methionine)
• Gepaktiv
• Ursodeoxycholic acid (ursodeoxycholic acid)

Snippet

Sponsor: Phenomen Pharma | Conditions: Metabolic Dysfunction-associated Fatty Liver Disease (MAFLD), Hepatomegaly | NA | Status: RECRUITING